Shikiar Asset Management Inc. Boosts Stake in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)

Shikiar Asset Management Inc. grew its holdings in shares of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) by 7.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,341 shares of the biopharmaceutical company’s stock after purchasing an additional 1,000 shares during the quarter. Shikiar Asset Management Inc. owned approximately 0.10% of Madrigal Pharmaceuticals worth $1,922,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Pearl River Capital LLC purchased a new stake in Madrigal Pharmaceuticals in the 4th quarter valued at about $29,000. First Mercantile Trust Co. increased its stake in Madrigal Pharmaceuticals by 52.2% during the fourth quarter. First Mercantile Trust Co. now owns 624 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 214 shares during the period. Quantamental Technologies LLC purchased a new stake in Madrigal Pharmaceuticals during the fourth quarter worth about $90,000. Great West Life Assurance Co. Can increased its stake in Madrigal Pharmaceuticals by 59.1% during the fourth quarter. Great West Life Assurance Co. Can now owns 985 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 366 shares during the period. Finally, Bessemer Group Inc. purchased a new stake in Madrigal Pharmaceuticals during the fourth quarter worth about $116,000. 56.29% of the stock is currently owned by institutional investors.

A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 18th. Citigroup cut their target price on shares of Madrigal Pharmaceuticals from $200.00 to $186.00 and set a “buy” rating on the stock in a research note on Wednesday, May 15th. HC Wainwright restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, May 9th. BidaskClub lowered shares of Madrigal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 18th. Finally, Cowen reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, April 17th. Two analysts have rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $222.09.

Shares of Madrigal Pharmaceuticals stock traded down $0.44 during trading hours on Friday, hitting $98.36. 118,570 shares of the company were exchanged, compared to its average volume of 211,486. Madrigal Pharmaceuticals Inc has a 1 year low of $91.56 and a 1 year high of $325.98. The stock has a market capitalization of $1.52 billion, a PE ratio of -44.31 and a beta of 1.07.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.00) by $0.02. During the same period in the previous year, the firm posted ($0.45) earnings per share. Sell-side analysts expect that Madrigal Pharmaceuticals Inc will post -4.25 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by Sundance Herald and is the property of of Sundance Herald. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://sundanceherald.com/2019/05/24/madrigal-pharmaceuticals-inc-mdgl-shares-bought-by-shikiar-asset-management-inc.html.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Read More: How Do You Calculate Return on Investment (ROI)?

Institutional Ownership by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply